Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07245784 · ClinicalTrials.gov registry record · NA
Radicle Clarity™ RBB: A Study Assessing the Impact of Health and Wellness Products on Cognitive Function and Related Health Outcomes
A NA study of Cognitive Function, sponsored by Radicle Science.
- Recruiting
- Registry status
- NA
- Development phase
- 850
- Enrollment target
- 1
- Study location
NCT07245784: Recruiting NA study of Cognitive Function, sponsored by Radicle Science.
NCT07245784 is a NA study of Cognitive Function that is actively recruiting participants, run by Radicle Science. The registered enrollment target is 850 participants, above the 455-participant average among 20 other Cognitive Function trials with a reported enrollment target (87% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07245784, a NA study of Cognitive Function, is actively recruiting participants, sponsored by Radicle Science.
- RECRUITING
- Registry status
- NA
- Development phase
- 850 participants
- Enrollment target
- 1
- Study location
Study Summary
A Randomized, Double-Blind, Placebo-Controlled Study Assessing the Impact of Health and Wellness Products on Cognitive Function and Related Health Outcomes
Primary Outcome
Change in cognitive function: Difference in rates of change over time in cognitive function score as assessed by PROMIS Cognitive Function 8A (scale 8-40; where lower scores correspond to worse cognitive function)
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Clarity Product Placebo Control
- DIETARY_SUPPLEMENT Clarity Active Product 1
Study Locations (1)
California
- Radicle Science Inc. - Del Mar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 850 participants |
| Start Date | 2025-12-04 |
| Est. Completion | 2026-12-04 |
| Phase | NA |
What NCT07245784 shows while recruiting
NCT07245784 is an interventional study that assigns participants to a tested intervention. The registered 850 participants enrollment target is mid-sized for trials with a published cap, above the 455-participant average among 20 other Cognitive Function trials with a reported enrollment target (87% higher).
The record links to 1 condition, with Cognitive Function appearing as the primary indexed condition, and to 2 interventions - of which Clarity Product Placebo Control is the first listed.
NCT07245784 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07245784 about?
NCT07245784 is a clinical study titled "Radicle Clarity™ RBB: A Study Assessing the Impact of Health and Wellness Products on Cognitive Function and Related Health Outcomes". A Randomized, Double-Blind, Placebo-Controlled Study Assessing the Impact of Health and Wellness Products on Cognitive Function and Related Health Outcomes
What is the current status of trial NCT07245784?
This trial is currently recruiting. It is a NA study. The enrollment target is 850 participants. The study started on 2025-12-04. Estimated completion is 2026-12-04.
What conditions does trial NCT07245784 study?
This clinical trial studies the following conditions: Cognitive Function.
What interventions are being tested in trial NCT07245784?
The interventions under investigation include: Clarity Product Placebo Control (DIETARY_SUPPLEMENT), Clarity Active Product 1 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07245784?
This trial is sponsored by Radicle Science, which has 55 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07245784 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognitive Function
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07245784's enrollment target sits among peer trials
850 3rd of 20 higher than 18 of 20 other Cognitive Function trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cognitive Function trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Brain Stimulation Effects on Cognitive Task Performance
RECRUITING · NA
-
Dose-Response Impact of Glucosyl-Hesperidin (CitraPeak) on Exercise Performance, Blood Flow, Stress, Cognition, and Other Perceptual Indicators
RECRUITING · NA
-
Effect of Daily Mixed Spice Consumption on Memory Function
RECRUITING · NA
-
IMST for Dementia Risk Reduction
RECRUITING · NA
-
Impact of a Novel Brain Longevity Supplement Containing the Postbiotic Urolithin A (Mitopure) on Cognitive Function and Related Health Outcomes
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03507257 · 850 participants
Longitudinal Early-onset Alzheimer's Disease Study Protocol
- NCT05846841 · 850 participants · NA
Personalized Tobacco Treatment in Primary Care (MOTIVATE)
- NCT05987059 · 850 participants · Phase 2
Involving Communities in Addressing the Maternal Health Crisis: Making an IMPACT
- NCT06289673 · 850 participants · Phase 4
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI